Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. It products are used for the treatment of chronic hepatitis B and shingles. ContraVir serves atients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. ContraVir is headquartered in Edison, New Jersey, the US.

ContraVir Pharmaceuticals Inc (CTRV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11

Venture Financing 12

Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12

Partnerships 13

ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13

Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14

Licensing Agreements 15

Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15

Equity Offering 17

ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17

ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18

ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19

ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20

ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22

ContraVir Pharma Spin Off from Synergy Pharma 23

ContraVir Pharma Completes Private Placement Of Securities For USD 3 Million 24

Debt Offering 25

ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25

Acquisition 26

ContraVir Pharma Acquires Ciclofilin Pharma 26

ContraVir Pharmaceuticals Inc-Key Competitors 27

ContraVir Pharmaceuticals Inc-Key Employees 28

ContraVir Pharmaceuticals Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Oct 03, 2018: ContraVir Pharmaceuticals names Robert Foster as acting Chief Executive Officer 30

Jun 20, 2018: ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements 31

Apr 09, 2018: ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board 32

Feb 05, 2018: Contravir Pharmaceuticals Receives Positive Nasdaq Listing Determination 33

Dec 29, 2017: ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer 34

Product News 35

11/27/2017: ContraVir Pharmaceuticals to Make Presentation on CRV431 at HEP DART 2017 35

11/27/2017: ContraVir Pharmaceuticals to Make Presentations at HEP DART 2017 36

10/12/2017: ContraVir Pharmaceuticals to Present Poster on CMX-157 at AASLD 2017 and Participate in Search for HBV / HDV Cure Analyst Day 37

10/12/2017: ContraVir Pharmaceuticals to Present two Posters on CRV-431 at AASLD 2017 38

09/19/2017: ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston 39

09/11/2017: ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex in the United States 40

09/06/2017: ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom 41

05/04/2017: ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex for Treatment of Hepatitis B Virus 42

04/22/2017: Data Enhances Understanding of ContraVir's Complementary Anti-HBV Compounds Tenofovir Exalidex and CRV431 43

04/12/2018: ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress 44

04/11/2017: ContraVir to Highlight New Data on Tenofovir Exalidex at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 46

04/11/2017: ContraVir to Present Data on CRV431 at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 47

04/04/2017: ContraVir's Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) 48

04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CMX-157 at the 53rd Annual International Liver Congress 49

04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CRV-431 at the 53rd Annual International Liver Congress 50

01/03/2017: ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B 51

Product Approvals 52

Feb 22, 2018: ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population 52

Feb 12, 2018: ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Leveraging the 505(b)(2) Regulatory Pathway 53

Clinical Trials 54

Feb 06, 2018: ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL 54

Oct 24, 2017: ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 55

Oct 19, 2017: ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL 56

Aug 08, 2017: ContraVir Pharmaceuticals Selected to Present Poster on TXL at the Upcoming AASLD Meeting 2017 57

Aug 03, 2017: ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting 2017 58

Apr 20, 2017: Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex Antiviral Activity in Hepatitis B Patients 59

Feb 14, 2017: ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex for Treating Hepatitis B 60

Other Significant Developments 61

Aug 06, 2018: Contravir Pharmaceuticals provides an update to corporate objective 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11

Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12

ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13

Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14

Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15

ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17

ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18

ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19

ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20

ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22

ContraVir Pharma Spin Off from Synergy Pharma 23

ContraVir Pharma Completes Private Placement Of Securities For USD 3 Million 24

ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25

ContraVir Pharma Acquires Ciclofilin Pharma 26

ContraVir Pharmaceuticals Inc, Key Competitors 27

ContraVir Pharmaceuticals Inc, Key Employees 28

ContraVir Pharmaceuticals Inc, Other Locations 29

ContraVir Pharmaceuticals Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ContraVir Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person